文献速递糖尿病肥胖与代谢综合征

PNPLA3 rs738409 C>G变异与体重变化交互影响肝脏脂肪变性和2型糖尿病风险

The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
PubMed 文献 · Diabetologia · 2019-01-23

研究基于上海长风研究2189名中老年成人,前瞻性监测4年体重变化、肝脏脂肪含量(LFC)和糖代谢指标。发现PNPLA3 GG基因型与体重增加交互作用加重肝脏脂肪变性和ALT升高,但降低糖负荷后2小时血糖升高幅度和2型糖尿病发病风险;该效应仅见于存在胰岛素抵抗或腹型肥胖的代谢不健康人群。

要点

  • PNPLA3 GG基因型携带者体重增加时肝脏脂肪和ALT升高更明显,但2型糖尿病风险更低。
  • 基因型与体重变化的交互作用对LFC和ALT显著(FDR校正交互P=0.044)。
  • 该效应仅见于代谢不健康(胰岛素抵抗或腹型肥胖)的参与者。

核心结论

  • PNPLA3 GG基因型与体重变化交互作用,加重代谢不健康人群的肝脏脂肪变,但降低新发2型糖尿病风险。

研究设计与样本

  • 前瞻性队列研究,纳入上海长风研究2189名中老年成人,监测4年体重变化、肝脏脂肪含量(定量超声)和糖代谢指标。

主要发现

  • PNPLA3 GG基因型解离了肝脏脂肪含量与OGTT 2小时血糖随4年体重变化的关系。
  • 相同体重增加程度下,GG基因型携带者LFC和血清ALT升高更多,但负荷后2小时血糖升高幅度和新发糖尿病风险低于CC基因型携带者。
  • 基因型与体重变化对LFC和ALT的交互作用显著(FDR校正交互P=0.044)。
  • 亚组分析显示GG基因型对LFC和负荷后2小时血糖变化的影响仅见于存在胰岛素抵抗或腹型肥胖的代谢不健康参与者。

临床怎么用

  • 对代谢不健康(胰岛素抵抗或腹型肥胖)的PNPLA3 GG基因型携带者,体重增加时需更关注肝脏脂肪变和ALT升高。
  • PNPLA3 GG基因型携带者体重增加时2型糖尿病风险可能相对较低,但肝脏脂肪变风险更高,临床管理应侧重肝脏保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The rs738409 C>G variant of the patatin-like phospholipase domain containing 3 gene (PNPLA3) increases the risk of non-alcoholic fatty liver disease (NAFLD) with no predisposition for insulin resistance. In this study, we aimed to investigate the influence of PNPLA3 polymorphisms on liver fat content (LFC) and glucose metabolic variables, and the associations between these, during the natural course of body weight changes in a Chinese adult cohort. METHODS: The LFC, measured using a quantitative ultrasound method, was prospectively monitored in 2189 middle-aged and elderly adults from the Shanghai Changfeng Study, together with changes in body weight and metabolic variables. General linear models were used to detect interactive effects between the PNPLA3 rs738409 genotype and 4 year changes in body weight on liver steatosis and glucose metabolism. RESULTS: The PNPLA3 homozygous GG genotype dissociated the changes in the LFC and OGTT 2 h post-load blood glucose (PBG) in relation to 4 year changes in body weight. PNPLA3 GG genotype carriers showed greater increases in the LFC and serum alanine aminotransferase (ALT) but lower PBG elevation and incident diabetes than PNPLA3 wild-type (CC) genotype carriers exhibiting the same degree of body weight increase. The interactions between the PNPLA3 genotype and changes in body weight on the LFC (false discovery rate [FDR]-adjusted pinteraction = 0.044) and ALT (FDR-adjusted pinteraction = 0.044) were significant. Subgroup analyses showed that the effect of the PNPLA3 GG genotype on changes in the LFC and PBG was only observed in metabolically unhealthy participants with insulin resistance or abdominal obesity. CONCLUSIONS/INTERPRETATION: The PNPLA3 GG genotype interacted with changes in body weight to aggravate liver steatosis but reduced the risk of incident type 2 diabetes in metabolically unhealthy participants.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Xia MF, Lin HD, Chen LY, et al. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes. Diabetologia. 2019. PMID: 30673802. doi:10.1007/s00125-018-4805-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。